Objective-To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Approach and Results-This was a 16-week, phase II, randomized, placebo-controlled, parallel-group study in type 2 diabetes mellitus patients with a urinary albumin/creatinine ratio of ≥300 mg/g using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, conducted in 17 tertiary referral hospitals. Eligible patients were randomized to probucol 250 mg/d (n=44), probucol 500 mg/d (n=41), and placebo (n=41) groups in a ratio of 1:1:1 after block randomization procedures, keeping the treatment assignment blinded to the investigators, patients, and study assistants. The primary end point was change in the geometric mean of urinary albumin/creatinine ratio from baseline to week 16 (ClinicalTrials.gov identifier NCT01726816). The study was started on November 8, 2012, and completed on March 24, 2014. The least squares mean change±SE from baseline in urinary albumin/creatinine ratio at week 16 was −7.2±639.5 mg/g in the probucol 250 mg/d group (n=43; P=0.2077 versus placebo group), 9.3±587.4 mg/g in the probucol 500 mg/d group (n=40; P=0.1975 versus placebo group), and 259.0±969.1 mg/g in the placebo group (n=41). Although the majority of subjects were on statins, probucol treatment significantly lowered total cholesterol and low-density lipoprotein cholesterol levels. QT prolongation occurred in one and two subjects in control and probucol 250 mg/d groups, respectively. 
D
espite the proven efficacy of renin-angiotensin-aldosterone system blockade, there is still a strong clinical need for additional therapy to reduce the residual risk for progression of diabetic kidney disease. Although multiple novel agents exerting vascular protective factors and antifibrotic, antioxidant, anti-inflammatory, and intracellular metabolic modulatory properties have been developed, none of these novel agents have shown clear efficacy for preventing or delaying diabetic kidney disease. 1, 2 Among the multiple mechanisms involving the chronic complication of hyperglycemia, oxidative stress has been suggested as one of the key players because it promotes protein kinase C and mitogen-activated protein kinase activation and the formation of advanced glycation end products. 3, 4 In streptozotocin-induced diabetic rats, lipid peroxidation products, 8-hydroxydeoxyguanosine, 5, 6 and compensatory enhancement of antioxidative enzymes 7 is found in the kidney. Induction of the antioxidant enzyme heme oxygenase-1, which is completely normalized by antioxidants such as vitamin E and probucol, has also been observed in the glomeruli of rats with diabetes mellitus. 8 In normoalbuminuric and microalbuminuric patients with type 2 diabetes mellitus, probucol significantly decreases the urinary type IV collagen excretion rate. 9 Such evidence has prompted clinical trials to prove the clinical benefit of probucol in diabetic kidney disease. In a single-center, open-label study, probucol decelerated the increase in the extent of proteinuria and delayed the decline in glomerular filtration rate in patients with baseline serum creatinine ≥2 mg/dL (n=40). 10 A larger scale (n=162), single-center, open-label study showed that probucol treatment delayed the initiation of chronic dialysis and renal dysfunction-related death in diabetes mellitus patients with urinary albumin excretion of >300 mg/g creatinine, with no significant difference in the extent of proteinuria between groups.
11 However, only a minority (<30%) of the study subjects in these clinical trials used 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins), 10 and use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor antagonist (ARBs) was not included in the eligibility criteria. Therefore, the benefit of probucol in patients with diabetic kidney disease has not been examined by a multicenter, double-blind, placebo-controlled trial in a population in which most subjects use both renin-angiotensin-aldosterone system blockade and statins.
This study aimed to determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using ACEIs or ARBs.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Among the eligible patients (n=126), 112 completed the study up to week 16 (placebo group, n=40; probucol 250 mg/d group, n=38; probucol 500 mg/d group, n=34; Figure 1 ). Demographics and baseline characteristics were well balanced between the groups (Table) . The proportion of subjects with glycated hemoglobin <7.0% (53 mmol/mol) was numerically (Figure 2) . The difference (least squares mean±SE) from the placebo group was −255.0±162.8 mg/g for the probucol 250 mg/d group and −264.3±165.8 mg/g for the probucol 500 mg/d group (P=0.2077 for probucol 250 mg/d , and P=0.1975 for probucol 500 mg/d groups). There was no difference in changes from baseline in urinary proteinto-creatinine ratio, urinary transferrin (not shown), urinary fibronectin (not shown), serum creatinine, estimated glomerular filtration rate, or cystatin-C levels among the groups.
The total cholesterol, low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol levels of the probucol 250 mg and 500 mg/d groups during the study period were lower than those of the placebo group (all were P<0.001 for both probucol 250 and 500 mg/d groups; Figure 3 ). Triglyceride (P=0.8704 for probucol 250 mg/d group and P=0.8819 for probucol 500 mg/d group) and oxidized LDL-C (P=0.5411 for probucol 250 mg/d group and P=0.2700 for probucol 500 mg/d group) levels were not different between groups ( Figure 3 ).
No differences in primary and secondary outcomes between groups were observed in subjects who did not use statins ( Figure II in the online-only Data Supplement). No differences in primary and secondary outcomes between groups were observed in the prespecified subgroup analyses according to statin use, baseline UACR, estimated glomerular filtration rate, serum creatinine, sex, and glycated hemoglobin (not shown). No differences in primary or secondary outcomes between the groups were observed when the diabetes mellitus duration was included as a covariate in the ANCOVA models as an exploratory analysis (not shown).
All 126 patients who participated in the study were included in the safety assessment, and 58 (46%) reported ≥1 adverse event (AE). The between-group differences were statistically insignificant for AEs and adverse drug reactions. AEs related to probucol occurred in 8 subjects in total, comprising 8 events. By treatment group, these events occurred in 4 subjects (9.09%; 4 events) in the probucol 250 mg/d group and 4 subjects (9.76%; 4 events) in the probucol 500 mg/d group. QT prolongation in ECG, which occurred in 2 subjects in probucol 250 mg/d group (4.55%; 2 events) and none in probucol 500 mg/d group was the most frequent adverse drug reaction in the probucol groups. Other adverse drug reactions developed in the probucol groups were "enteritis," "rash," "diarrhea," " nausea," and "dizziness." AEs causing death did not occur in this study and additional serious AEs occurred in 8 subjects (6.35%), comprising 16 events, and all were judged unrelated to the IPs (Table I in the online-only Data Supplement). 
Discussion
To the best of our knowledge, this was the first multicenter, double-blind, randomized, placebo-controlled trial to examine the efficacy and safety of probucol in patients with diabetic kidney disease in which the majority of the subjects used statins and all subjects used ACEIs/ARBs. Although lower levels of total and LDL-C were achieved in subjects allocated to the probucol 250 and 500 mg/d groups, there was no difference in the rate of progression of albuminuria between groups.
The results of this multicenter, double-blind, placebo-controlled study are in contrast with previous open-label studies in which probucol suppressed the progression of proteinuria and decline in renal function. 10, 11 In addition to the open-label study design of the previous studies, the different proportions of subjects who used ACEIs/ARBs could explain the discrepancy. In a previous study, 17.6% of subjects in probucol group and 21.6% in the control group used ACEIs/ARBs, 10 and a significant reduction in urinary protein excretion in the probucol group was observed. 10 No significant change in UACR was observed in another study, in which 86% of the subjects in the probucol group and 83% in the control group used ACEIs/ ARBs. 11 Because all subjects in the current study used ACEIs/ ARBs with no change in dose for at least 3 months before screening, the use of ACEIs/ARBs could have masked the benefit of probucol in terms of UACR. The study period of 4 months in the current study could have been too short to evaluate the long-term benefits of probucol, such as the delay in chronic hemodialysis therapy initiation seen in previous studies.
10,11 A recent study by Zhu et al 12 additionally reported the superior efficacy of probucol plus telmisartan to that of telmisartan alone in terms of proteinuria extent. In the study by Zhu et al, 12 a fixed dosage of telmisartan (80 mg once daily) was given with or without probucol after a 4-week run-in period during which a fixed dosage of telmisartan (80 mg once daily) was given and other ACEIs/ARBs were stopped if they were used before the study period. Therefore, the study was not designed to examine the additional benefit of probucol when added to the optimized dosage of ACEIs/ARBs, and the proportion of subjects who used ACEIs/ARBs before the run-in period was not provided. 12 In the current study, probucol did not decrease the oxidized LDL level (Figure 3) . However, this finding does not preclude an antioxidative effect of probucol because it has been suggested that the protective effect of probucol depends not on its ability to inhibit lipid oxidation, but on its ability to induce the stress-induced anti-inflammatory enzyme heme oxygenase-1. 13, 14 Alternatively, suboptimal concentrations in this study might have affected the observed lack of difference in oxidized LDL-C level. In a recent study that showed the superior efficacy of probucol plus telmisartan to that of telmisartan alone in terms of proteinuria extent, the dosage of probucol was 1000 mg/d (500 mg twice daily) for the first 24 weeks and then 500 mg/d (250 mg twice daily) for an additional 24 weeks. 12 The protective effect of probucol in contrast-induced acute kidney injury has also been reported [15] [16] [17] presumably because of the antioxidant effect of probucol. The dosage of probucol in these studies, 1000 mg orally before the procedure and then 500 mg twice daily for 3 days, was much higher than that of the current study.
In the current study, 86 of 126 (68%) subjects used statins, whereas a minority (14%-26%) of study subjects in the previous studies used statins. 10, 11 However, a significant additional LDL-C-lowering effect of probucol was observed in this study. As probucol upregulates the fractional catabolic rate of LDL-C via an LDL receptor-independent pathway and increasing bile acid synthesis, 18, 19 its effect on LDL-C lowering might be complementary to that of statins. Indeed, a recent animal study showed that a combination of probucol and atorvastatin produced a significantly greater reduction in area of the atherosclerotic lesion in high fat-fed rabbits than that of atorvastatin monotherapy. 20 To date, however, it is unclear whether the combination of probucol and statins has additional lipid-lowering and antiatherosclerotic effects compared with statin monotherapy in diabetic kidney disease because of the limited clinical use of probucol after the introduction of statins. Nevertheless, the additional LDL-C-lowering effect of probucol observed in the current study is noteworthy given the lack of an additional LDL-C-lowering effect of probucol compared with lovastatin monotherapy in a previous study conducted in patients with familial hypercholesterolemia. 21 Administration of probucol up to 500 mg/d was well tolerated. All adverse drug reactions resolved after appropriate treatment and were predictable. Probucol may be safely administered in patients with diabetic nephropathy, with a monitoring of QT prolongation by conducting a periodic ECG.
Several limitations of this study should be discussed. First, the sample size was calculated based on a previous randomized, open-label study, which is supposed to have overestimated the cause and effect relationship because of potential biases underlying the open-label design. 10 Therefore, the current study might be underpowered to demonstrate the benefit of probucol in albuminuric type 2 diabetes mellitus patients. Second, the proportion of patients on statins was also greater than those in previous studies. In fact, the benefit of statins and their antioxidative/antiinflammatory effects in diabetic nephropathy has been welldemonstrated. 15, 22, 23 Therefore, the results of this study do not preclude the benefit of probucol in statin-intolerant or statin-naive patients with diabetic kidney disease, and the sample size calculation based on the previous studies including limited proportions of statin-using patients also support the inadequate power of this study.
In conclusion, treatment with probucol up to 500 mg/d for 4 months failed to reduce urinary albumin in type 2 diabetes mellitus patients on ACEI/ARBs with a baseline UACR of >300 mg/g. This regimen neither changed the rate of decline in renal function nor suppressed levels of oxidized LDL although it did significantly lower total and LDL-cholesterol levels. In type 2 diabetes mellitus patients with diabetic nephropathy using ACEI/ARBs and statins, demonstration of a protective effect on the nephropathy may require adequately powered further study with longer-term treatment using a higher dosage sufficient to exert antioxidative effects.
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• This was the first multicenter, double-blind, randomized, placebo-controlled trial to examine the efficacy and safety of probucol in patients with diabetic kidney disease in which the majority of the subjects used statins and all subjects used angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
• Although lower levels of total and low-density lipoprotein-cholesterol were achieved in subjects allocated to the probucol 250 and 500 mg/d groups, there was no difference in the rate of progression of albuminuria between groups.
• The results of this study indicate that demonstration of protective effect of probucol as an add-on therapy to statins on the diabetic nephropathy may require adequately powered further study with longer-term treatment of a higher dosage sufficient for antioxidative effect.
